caa a22 4500 477058159 CHVBK 20180405111352.0 cr unu---uuuuu 170330e19960201xx s 000 0 eng 10.1007/BF00203777 doi (NATIONALLICENCE)springer-10.1007/BF00203777 Effects of hydrochlorothiazide and captopril on lipoprotein lipid composition in patients with essential hypertension [Elektronische Daten] [J. Bagdade, W. Buchanan, T. Pollare, H. Lithell] Objective: Effective antihypertensive agents may differ in their capacity to reduce cardiovascular risk because they induce potentially atherogenic alterations in lipoprotein composition. Patients: To assess this possibility, the effects of five months' treatment with either hydrochlorothiazide (HCTZ) or the converting enzyme inhibitor captopril (CAPT) on lipoprotein lipid composition were compared in thirty normolipidaemic patients with essential hypertension (EH). Results: The sixteen patients treated with HCTZ showed the expected directional alterations in plasma TG (+31%), HDL2-C (-16%), and CHOL (+7.6%); in contrast TG and CHOL were unchanged after captopril in fourteen patients and their HDL2-C declined (-16%). Neither drug altered lipoprotein core lipid composition, but small increases were observed in the HDL2 sphingomyelin/lecithin ratio after both agents. The plasma free (unesterified) cholesterol (FC) lecithin (L) ratio, a new index of cardiovascular risk, was abnormally increased before treatment and was not altered by either drug. Conclusion: These findings indicate that HCTZ and CAPT treatment have small, but demonstrable effects on lipoprotein surface lipid composition in patients with EH that are confined to the HDL2 subfraction. Springer-Verlag, 1996 Hydrochlorothiazide nationallicence Captopril nationallicence Hypertension nationallicence lipoprotein composition nationallicence Bagdade J. Rush-Presbyterian-St. Luke's Medical Center, 1653 West Congress Parkway, 60612, Chicago, IL, USA aut Buchanan W. Rush-Presbyterian-St. Luke's Medical Center, 1653 West Congress Parkway, 60612, Chicago, IL, USA aut Pollare T. Department of Geriatrics, Uppsala University, Uppsala, Sweden aut Lithell H. Department of Geriatrics, Uppsala University, Uppsala, Sweden aut European Journal of Clinical Pharmacology Springer-Verlag 49/5(1996-02-01), 355-359 0031-6970 49:5<355 1996 49 228 https://doi.org/10.1007/BF00203777 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00203777 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Bagdade J. Rush-Presbyterian-St. Luke's Medical Center, 1653 West Congress Parkway, 60612, Chicago, IL, USA aut NATIONALLICENCE 700 1- Buchanan W. Rush-Presbyterian-St. Luke's Medical Center, 1653 West Congress Parkway, 60612, Chicago, IL, USA aut NATIONALLICENCE 700 1- Pollare T. Department of Geriatrics, Uppsala University, Uppsala, Sweden aut NATIONALLICENCE 700 1- Lithell H. Department of Geriatrics, Uppsala University, Uppsala, Sweden aut NATIONALLICENCE 773 0- European Journal of Clinical Pharmacology Springer-Verlag 49/5(1996-02-01), 355-359 0031-6970 49:5<355 1996 49 228 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer